Atosiban Versus Placebo for Threatened Preterm Birth (APOSTEL 8): A Multicentre, Randomised Controlled Trial

( Lancet . 2025;405:1004-13. doi: 10.1016/S0140-6736(25)00295-8.) International guidelines suggest tocolysis in cases of threatened preterm birth (tPTB), due to both successes in and the general importance of prolonging labor in order for fetal development. Use of tocolysis also generally allows time for corticosteroids to be delivered to the mother, which subsequently accelerates fetal lung development. Despite these benefits, improved neonatal outcomes have not necessarily been identified as a direct result of tocolysis. The tocolytic drug atosiban is one of the two most used in pregnancy, due to lowered risk to the fetus. The Assessment of Perinatal Outcome after Specific Tocolysis in Early Labor (APOSTEL) 3 trial demonstrated that atosiban is successful at prolonging pregnancy, and the data suggested that lowered neonate mortality rates are more likely with atosiban, compared with the alternative drugs used. The publication discussed here reports on the APOSTEL 8 trial, which specifically examined the effectiveness of atosiban in improving neonatal outcomes.